FUROSEMIDE (furosemide) by Molecular Devices is clinical pharmacology investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs, and various clearance studies in both humans and experimental animals. First approved in 1983.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
Furosemide is a loop diuretic that inhibits sodium and chloride absorption in the proximal tubule, distal tubule, and loop of Henle, making it one of the most potent diuretics available. It is used to treat edema associated with congestive heart failure, renal disease, and hepatic cirrhosis, as well as hypertension. The drug has a rapid onset (within 1 hour) and peak effect within 1–2 hours, with a duration of 6–8 hours.
As a mature, approaching loss of exclusivity product with high generic competition, roles focus on cost management, generic transition planning, and off-label or combination strategies rather than growth-oriented expansion.
CLINICAL PHARMACOLOGY Investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs, and various clearance studies in both humans and experimental animals. It has been demonstrated that furosemide inhibits primarily the absorption of…
Worked on FUROSEMIDE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Loop Diuretic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bumetanide vs. Furosemide in Cirrhosis
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers
A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on furosemide offers limited growth trajectory and career progression; the role is primarily defensive, focused on managing generic erosion, maintaining market access, and optimizing manufacturing and distribution. Pharma professionals should evaluate this opportunity if seeking stability in a legacy asset role rather than high-growth commercial development.